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Sex Med 2Introduction: Long-term adverse symptoms of men who used oral ﬁnasteride against androgenic alopecia have
been recently described as post-ﬁnasteride syndrome (PFS).
Aim: To determine whether (CAG)n-rs4045402 and (GGN)n-rs3138869 polymorphisms in the androgen
receptor (AR) gene are implicated in PFS.
Methods: AR polymorphisms were studied according to PFS symptoms in 66 white participants (31.8% Italian,
28.8% American, and 39.4% other).
Main Outcome Measures: Symptoms were investigated by an ad hoc 100-item questionnaire and the Arizona
Sexual Experience Scale and Aging Male Symptom Scale (AMS). (CAG)n and (GGN)n repeats were categorized
as short ([CAG]9e19, [GGN]<23), medium ([CAG]20e24, [GGN]23), or long ([CAG]25e37, [GGN]>23).
Results: Median age was 32 years, duration of ﬁnasteride use was 360 days, and time from ﬁnasteride discontin-
uation was 1,053 days. We observed several frequency differences in symptoms according to (CAG)n and (GGN)n
repeat numbers. Three AMS items were worse for medium (GGN)23 than for long (GGN)>23 carriers and one item
was worse for short (GGN)<23 carriers. The AMS item for decrease in sexual desire or libido was worse for short
(CAG)9e19 carriers than for medium (CAG)20e24 carriers. Through the ad hoc questionnaire, signiﬁcant ﬁndings
in (CAG)n and/or (GGN)n repeats were obtained for penile discomfort, loss of scrotal sensitivity, scrotal discomfort,
less pubic hair, loss of perceived perineal fullness, increased sperm density, involuntary muscle spasms, loss of muscle
tone, increased weight (>2 kg), increased skin dryness, and onset of symptoms after ﬁnasteride use.
Conclusion: This study showed that short and/or long (CAG)n and (GGN)n repeats had different frequencies
according to symptoms reported by patients with PFS, likely reﬂecting the vast array of genes modulated by the
AR. This study showed a U-curvilinear proﬁle of (CAG)n repeats for skin dryness symptoms, where the two
extremes exhibited a worse condition than medium repeats. Further studies are necessary to investigate the PFS
pathophysiology using a precision medicine approach. Cauci S, Chiriacò G, Cecchin E, et al. Androgen
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Recent studies have described severe adverse effects in young
men who used oral ﬁnasteride against androgenic alopecia (AGA)
that persisted several months or years after ﬁnasteride dis-
continuation1e5 (a condition called post-ﬁnasteride syndrome
[PFS]4,6). A meta-analysis of clinical trials of ﬁnasteride on
subjects with AGA showed that the toxicity information was very
limited, of poor quality, and likely to be systematically biased.7
Finasteride inhibits 5a-reductase, the enzyme responsible for
the reduction of testosterone into dihydrotestosterone.5 Finas-
teride against AGA (male pattern hair loss) is used at lower
dosage (1 mg/d) than against benign prostatic hyperplasia
(5 mg/d). Finasteride inhibits 5a-reductase type 2 and 3 enzymes
much more strongly than the type 1 enzyme8,9; therefore,
ﬁnasteride can affect several different human tissues,4,5,8,10 such
as the prostate, muscle, liver, kidney, brain, mammary gland,
frontal cortex, skin, epidermis, pancreas, spleen, heart, testicle,
stomach, dermis, small intestine, and adipose tissues.8,9,11
Finasteride use has several adverse effects, including erectile
dysfunction, loss of libido, and smaller ejaculatory volume.5,10,12
A meta-analysis on the effects of 5a-reductase inhibitors found a
signiﬁcant pooled relative risk for sexual dysfunction in men with
benign prostatic hyperplasia (2.56, 95% CI ¼ 1.48e4.42) but
no signiﬁcant increased risk in men with AGA (1.21, 95%
CI ¼ 0.85e1.72).13
Recently, a clinical study described the main symptoms of
subjects with PFS, including loss of penis sensitivity, decreased
ejaculatory force, low penile temperature, smaller ejaculatory
volume, anhedonia, lack of mental concentration, and loss of
muscle tone or mass.4 In particular, an immunohistochemical
study found increased levels of the androgen receptor (AR) in
epithelial and stromal cells from the foreskin of eight men with
PFS compared with healthy men.14
The expression level and amino acid protein sequence of AR
can be affected by polymorphisms in its gene (AR).15 The most
frequently studied polymorphisms of AR are two repeated nucle-
otide sequences: the (CAG)nCAA repeat nucleotide sequence,
denoted as (CAG)n, encoding a polyglutamine stretch, and the
polymorphic repeat (CGT)3GGG(GGT)2(GGC)n, denoted as
(GGN)n, encoding a poly-glycine stretch. The two poly-
morphisms are included in the N-terminal of the AR protein and
compose the transactivation domain of the nuclear receptor.16
The (CAG)n repeat length usually spans 9 to 36 repeat units,
although the number varies among ethnic groups.17 Long (CAG)
n repeats have been associated with decreased AR transactivation
activity and weaker transcriptional potential than short repeats.18
CAG expanded repeats of at least 40 have been found in
Kennedy disease, a neurodegenerative syndrome also character-
ized by androgen insensitivity.18e20 Long (CAG)n repeats have
been associated with male infertility,21 although studies have
been inconsistent.17,18,21 In contrast, a meta-analysis suggested
that a shorter (CAG)n repeat polymorphism in Caucasians andAsians might increase the risk of prostate cancer compared with
the longer (CAG)n repeat.22
The trinucleotide (GGN)n has been less investigated than the
(CAG)n repeat polymorphism with respect to male androge-
nicity and infertility. Moreover, studies have not been very
consistent.21 In an in vitro study, (GGN)23 showed higher
transcription than shorter or longer repeats.23 A meta-analysis
found a correlation of long (GGN)23 with testicular cancer.24
A recent molecular study (of 69 men with AGA and PFS, 91
men with untreated AGA, and 78 healthy men without AGA)
focused on whether the two polymorphisms, (CAG)n-rs4045402
and (GGN)n-rs3138869, in the AR gene might play a role in the
toxic long-term effects of ﬁnasteride.6 This study suggested that
extreme repeats are a genetic predisposing factor for AGA
development.
However, the pathophysiology of PFS remains largely
unknown and detailed molecular events predisposing to speciﬁc
long-term symptoms experienced by patients with PFS remain
obscure.5
In our previous genetic study,6 we did not examine the rela-
tion of AR (CAG)n and (GGN)n polymorphisms with the single
speciﬁc symptoms of subjects with PFS. In the present study, we
explored this relation by three different questionnaires—the
Arizona Sexual Experience Scale (ASEX),25 the Aging Male
Symptom Scale (AMS),26 and our ad hoc 100-item
questionnaire4—for the clinical symptoms of 66 men with
PFS. We also collected retrospectively the genetic data from
our previous study6 to check whether less common repeat
lengths of (CAG)n-rs4045402 and (GGN)n-rs3138869
polymorphisms might be related to the speciﬁc symptoms
described by subjects with PFS.METHODS
Subjects
Enrollment, inclusion, and exclusion criteria were previously
described.4,6 Obese subjects (body mass index > 30.0 kg/m2)
were excluded from this study because of the relation of fat body
composition to androgens.27 According to the inclusion criteria,
all participants were white.28 Moreover, because of the location
of AR in the X chromosome, and to further conﬁrm race, each
participant was speciﬁcally asked to declare whether he had a
white mother.6 None of the subjects declared homo- or bisex-
uality. The institutional ethical committee of each participating
institution approved the study protocol (according to the
Declaration of Helsinki), and all subjects signed a written
informed consent.
This was an observational and retrospective study. We
enrolled men (18 and 50 years old) who used oral ﬁnasteride
for AGA and had developed persistent adverse effects lasting for
at least 6 months after drug discontinuation.4,6 Of 69 men
initially enrolled,6 three were excluded for incompleteSex Med 2017;5:e61ee71
AR Polymorphisms and Post-Finasteride Syndrome e63questionnaires, leaving 66 subjects with PFS to be examined.
Finasteride was used orally mostly at the dose of 1 mg/d, but
some patients (to save money) broke a 5-mg pill into four parts
(w1.25 mg/d) or broke a 1-mg pill into two parts (w0.5 mg/d).Assessment of Symptoms and AR Polymorphisms
Three different questionnaires were used to evaluate adverse
effects persisting longer than 6 months. We developed an ad hoc
100-item questionnaire to interview subjects with PFS about their
demographic and clinical characteristics.4 In addition, participants
ﬁlled out the ASEX25 reporting on their condition at the time of
study (current ASEX) and retrospectively in addressing how they
were before ﬁnasteride use (pre-ASEX) to rule out any sexual
dysfunction before they started to use ﬁnasteride. However,
because of possible recall bias for data before ﬁnasteride use, the
pre-ASEX score was not used further to analyze the role of AR
polymorphisms. The ASEX consists of ﬁve items with rating scales
graded from 1 to 6 that quantify sex drive, arousal, penile erection,
ability to reach orgasm, and satisfaction from orgasm, with higher
scores indicating more severe sexual dysfunction.
Furthermore, participants ﬁlled out the 17-item AMS assess-
ing androgenic dysfunction26,29 by three subscales for psycho-
logical, somatic, and sexual symptoms. Each item is graded from
1 (absent) to 5 (very severe); the total AMS score deﬁnes
androgen deﬁciency as absent (score ¼ 17e26), slight (score ¼
27e36), moderate (score ¼ 37e49), or severe (score  50).26
The present inclusion criteria were a current ASEX total score
corresponding to sexual dysfunction (total ASEX score  19 or
any one item score ¼ 5 or any three items with score  4)25
and/or AMS total score of least 27.4 Exclusion criteria
included an ASEX score of at least 19 before ﬁnasteride use.4
For assessment of AR (CAG)n and (GGN)n polymorphisms,
genomic DNA was extracted from blood or saliva samples,
ampliﬁed, and sequenced as described previously.6Statistical Analysis
AR (CAG)n and (GGN)n repeat lengths were divided into
three categories—low quartile (<25th percentile, short repeats),
interquartile (25th to 75th percentile, medium repeats), and high
quartile (>75th percentile, long repeats)—and analyzed in a
binary logistic regression model. For (GGN)n repeats, the central
(GGN)23 repeat was found in more than 50% of subjects (44 of
66, 67%); therefore, short repeats (GGN)<23 and long repeats
(GGN)>23 necessarily had a frequency lower than 25%.
The Kolmogorov-Smirnov test was adopted to assess the
normal data distribution. Continuous data not normally
distributed were expressed as median (25th to 75th percentile,
interquartile range) and comparisons between groups were per-
formed by Mann-Whitney U-test. Odds ratios (ORs) and 95%
CIs were calculated to assess relative risks for binary (yes or no)
variables, and the Pearson c2 or Fisher test was used to calculate
the P value, as appropriate. Two-sided P values less than .05 wereSex Med 2017;5:e61ee71considered signiﬁcant (P < .10 indicated a tendency). SPSS for
Windows (IBM Corp, Armonk, NY, USA) was used.RESULTS
Demographic characteristics and results from the ad hoc
questionnaire, ASEX, and AMS are presented in Table 1. Sub-
jects were enrolled a median of nearly 3 years after ﬁnasteride
discontinuation and had used ﬁnasteride for 12 months.
Distribution of (CAG)n and (GGN)n repeat frequencies in the
66 subjects with PFS is illustrated in Supplementary Figures S1 and
S2, respectively. Frequencies of subjects with short, medium, and
long repeat lengths for the two polymorphisms were categorized:
short ¼ (CAG)9e19 (n ¼ 18, 27.3%) and (GGN)<23 (n ¼ 8,
12.1%); medium ¼ (CAG)20e24 (n ¼ 37, 56.1%) and (GGN)
23 (n ¼ 44, 66.7%); long ¼ (CAG)25e37 (n ¼ 11, 16.7%) and
(GGN)>23 (n ¼ 14, 21.2%).
We did not ﬁnd signiﬁcant differences among the subgroups
of (CAG)n and (GGN)n repeat lengths for age at enrollment, age
at starting drug use, duration of ﬁnasteride use, period from drug
discontinuation to study enrollment, and body mass index
(Table 2). However, we observed a decreasing trend for duration
of ﬁnasteride use and decrease of (CAG)n repeats with median
values of 620 days for long (CAG)25e37, 450 days for medium
(CAG)20e24, and 180 days for short (CAG)9e19 (short
repeats showed a tendency to differ from medium repeats
[P ¼ .062], but the difference for short [CAG]9e19 vs medium
to long [CAG]20 was signiﬁcant [P ¼ .045]).
Table 2 presents ﬁndings from the ASEX and AMS. The
total scores of the ASEX and AMS did not differ with length of
(CAG)n and (GGN)n repeats; however, we found differences
for single items. For clarity, Table 2 presents only symptom
items that showed a median number of points that differed
statistically between at least two repeat length groups. ASEX
item 5 (orgasm satisfaction) was worse in the long (CAG)
25e37 than in the short (CAG)9e19 subgroup (P ¼ .040).
Five AMS items showed differences among (CAG)n and/or
(GGN)n subgroups. AMS item 5 (increased need for sleep
and/or often feeling tired) was higher in the medium (GGN)23
than in the short (GGN)<23 group (P ¼ .048). AMS items 9
(physical exhaustion or lacking vitality), 11 (depressive mood),
and 12 (feeling that one has passed one’s peak) were worse in
the medium (GGN)23 than in the long (GGN)>23 subgroup
(P ¼ .042, P ¼ .036, and P ¼ .044, respectively). In contrast,
AMS item 17 (decrease in sexual desire/libido) was worse in the
short (CAG)9e19 than in the medium (CAG)20e24 group
(P ¼ .028).
Tables 3 and 4 present data collected by the ad hoc ques-
tionnaire. Data were reported as binary variables, and only
symptom items with at least one signiﬁcant ﬁnding in relation to
(CAG)n and/or (GGN)n repeats, respectively, were indicated.
Table 3 presents signiﬁcant ﬁndings in relation to (CAG)n
repeats. Scrotal discomfort was less frequent in the short
Table 1. Demographic characteristics, ﬁnasteride use, and
symptoms of 66 subjects with post-ﬁnasteride syndrome
Age (y), median (25the75th
percentile), range
32 (27e39), 21e50
BMI (kg/m2), median (25the75th
percentile), range
23.9 (22.4e26.2),
17.3e29.9
Nationality, n (%)
Italy 21 (31.8)
United States 19 (28.8)
Canada 9 (13.6)
United Kingdom 6 (9.1)
France 3 (4.5)
Spain 2 (3.0)
Bulgaria 1 (1.5)
Hungary 1 (1.5)
Sweden 1 (1.5)
Australia 1 (1.5)
Brazil 1 (1.5)
Israel 1 (1.5)
Educational level, n (%)
Elementary school 1 (1.5)
High school 15 (22.7)
College or university 50 (75.8)
Marital status, n (%)
Single 54 (81.8)
Married 9 (13.6)
Divorced 3 (4.5)
Age at starting ﬁnasteride (y),
median (25the75th
percentile), range
26 (22e31), 18e48
Duration of ﬁnasteride use
(d), median (25the75th
percentile), range
360 (163e1,298),
17e3,650
Discontinuation of ﬁnasteride
(d), median (25the75th
percentile), range
1,053 (560e2,043),
181e5,057
Dosage used, n (%)
1 mg/d 46 (69.7)
1.25 mg/d 16 (24.2)
0.5 mg/d 4 (6.1)
Onset of symptoms, n (%)
During ﬁnasteride use 59 (89.4)
After ﬁnasteride use 7 (10.6)
1 mo after discontinuation 5 (7.6)
>1 mo after discontinuation 2 (3.0)
Trend of symptoms after
ﬁnasteride discontinuation, n (%)
Worsening 38 (57.6)
Unchanged 19 (28.8)
Improved 9 (13.6)
Sexual symptoms, n (%)*
Loss of penis sensitivity 58 (87.9)
Decreased ejaculatory force 54 (81.8)
Decreased penile temperature 49 (74.2)
Decreased ejaculate volume 47 (71.2)
Loss of scrotum fullness 45 (68.2)
(continued)
Table 1. Continued
Penile ﬂaccidity or wrinkled 42 (63.6)
Decrease of penile dimension 42 (63.6)
Loss of scrotum sensitivity 41 (62.1)
Mental disorders, n (%)*
Decreased pleasure in life or
emotions (anhedonia)
51 (77.3)
Lack of mental concentration 49 (74.2)
Somatic symptoms, n (%)*
Loss of muscle tone or mass 34 (51.5)
AMS total score (points), median
(25the75th percentile), range
52 (44e61), 29e75
Somato-vegetative
subscale (points)
19 (16e24), 9e30
Psychological subscale (points) 15 (11e19), 5e25
Sexual subscale (points) 19 (16e21), 10e23
AMS total score < 37 points
(slight clinical androgen
deﬁciency), n (%)
3 (4.5)
AMS total score  50 points
(severe clinical androgen
deﬁciency), n (%)
38 (57.6)
Current ASEX total score (points),
median (25the75th
percentile), range
22 (19e23), 15e30†
Current ASEX total score
19 points (severe sexual
dysfunction), n (%)
52 (78.8)
ASEX total score before
ﬁnasteride use (points),
median (25the75th
percentile), range
7 (6e10), 5e15†
ASEX total score 19 points
before ﬁnasteride use (severe sexual
dysfunction), n (%)
0 (0.0)
AMS ¼ Aging Male Symptom Scale; ASEX ¼ Arizona Sexual Experience
Scale; BMI ¼ body mass index.
*Most frequent symptoms obtained from the authors’ ad hoc 100-item
questionnaire.
†P < .001, current ASEX score vs ASEX score before ﬁnasteride use.
e64 Cauci et al(CAG)9e19 than in the medium (CAG)20e24 and medium to
long (CAG)20 groups (33.3%, P ¼ .027). Increase of sperm
density was not reported by subjects with short (CAG)9e19
repeats but was noted by 40.5% of men with medium (CAG)
20e24 (P ¼ .001) repeats and by 35.4% of men with medium
to long (CAG)20 repeats (P ¼ .003). The ORs were 6.3 for
involuntary muscle spasms in the long (CAG)25e37 vs medium
(CAG)20e24 group and 5.5 vs the medium to short (CAG)<25
(39.6%, P ¼ .019) group. Increase of body weight (>2 kg) had
an OR equal to 4.9 for the long (CAG)25e37 vs medium
(CAG)20e24 group.
Notably, perceived increased skin dryness showed a curvi-
linear U-proﬁle according to (CAG)n length. The mediumSex Med 2017;5:e61ee71
Table 2. Comparison of subgroups of patients with post-ﬁnasteride syndrome according to AR gene (CAG)n and (GGN)n short, medium, and long repeats*
(CAG)9e19
repeats, short
(n ¼ 18)
(CAG)20e24
repeats, medium
(n ¼ 37)
(CAG)25e37
repeats, long
(n ¼ 11)
P value
(GG)<23
repeats, short
(n ¼ 8)
(GGN)23
repeats, medium
(n ¼ 44)
(GGN)>23
repeats, long
(n ¼ 14)
P value
Short vs
medium
Long vs
medium
Short vs
long
Short vs
medium
Long vs
medium
Short
vs long
Age (y) 34.5 (26.7e42.2) 32.0 (26.5e37.5) 31.0 (27.0e41.0) .25 .94 .39 36.0 (30.7e38.7) 31.0 (26.2e37.5) 34.5 (26.7e44.0) .18 .25 .95
Age at starting
ﬁnasteride (y)
29.7 (23.1e36.9) 26.3 (21.9e30.6) 24.4 (20.8e32.6) .070‡ .72 .15 27.2 (25.6e32.9) 24.3 (21.9e30.6) 28.9 (21.8e38.8) .094‡ .22 .78
Duration of
ﬁnasteride
use (d)
180 (57e456) 450 (168e2,115) 620 (241e1,218) .062‡ .98 .11 1,659 (105e2,671) 335 (170e1,095) 317 (120e1,004) .20 .70 .29
Discontinuation of
ﬁnasteride (d)
1,026 (536e2,286) 1,073 (561e1,715) 1,090 (617e2,128) .80 1.00 .96 561 (234e1,745) 1,073 (567e2,051) 1,131 (889e2,282) .23 .54 .088‡
BMI (kg/m2) 24.0 (22.1e26.7) 23.7 (22.3e25.9) 24.5 (22.7e26.9) .51 .39 .79 25.8 (24.2e27.5) 23.3 (22.5e25.1) 23.9 (22.1e27.0) .080‡ .85 .37
ASEX
Total score 20.5 (17.7e24.0) 21.0 (19.0e23.0) 22.0 (20.0e23.0) .86 .45 .65 23.0 (19.0e23.7) 22.0 (19.0e23.7) 20.0 (17.0e22.5) .43 .31 .23
Item 5, orgasm
satisfaction
3.5 (3.0e4.0)† 4.0 (3.0e4.5) 4.0 (4.0e5.0)† .25 .21 .040† 4.0 (3.0e5.0) 4.0 (3.0e4.7) 4.0 (3.7e4.0) .71 .99 .68
AMS
Total score 52.0 (47.5e54.7) 52.5 (44.0e62.7) 48.0 (42.0e64.0) .84 .96 .89 52.0 (48.2e61.5) 53.0 (44.0e61.5) 47.0 (40.5e60.0) .93 .31 .42
Item 5, need for
sleep and/or
often feeling
tired
4.0 (2.0e4.0) 3.0 (2.0e4.0) 3.0 (3.0e4.0) .18 .52 .50 2.5 (1.2e3.0)† 3.0 (2.0e4.0)† 3.0 (2.0e4.0) .048† .25 .39
Item 9, physical
exhaustion or
lacking vitality
3.5 (2.0e4.0) 3.0 (2.2e4.0) 3.0 (3.0e5.0) .91 .60 .69 3.0 (3.0e4.0) 4.0 (3.0e4.0)† 3.0 (1.5e4.0)† .39 .042† .41
Item 11, depressive
mood
3.0 (2.0e3.2) 4.0 (2.0e4.0) 2.0 (3.0e3.0) .27 .32 .60 2.5 (1.2e4.0) 3.0 (3.0e4.0)† 2.0 (1.5e4.0)† .31 .036† .68
Item 12, feeling
that you have
passed your
peak
3.5 (3.0e5.0) 4.0 (3.0e4.7) 3.0 (2.0e4.0) .96 .39 .42 4.0 (3.0e4.0) 4.0 (3.0e5.0)† 3.0 (1.5e4.0)† .86 .044† .106
Item 17, decrease
in sexual desire
or libido
5.0 (5.0e5.0) 4.0 (4.0e5.0) 5.0 (4.0e5.0) .028 .59 .15 4.5 (4.0e5.0) 5.0 (4.0e5.0) 5.0 (3.5e5.0) .95 .96 1.00
AMS ¼ Aging Male Symptom Scale; ASEX ¼ Arizona Sexual Experience Scale; BMI ¼ body mass index.
*Continuous variables are reported as median (25the75th percentile or interquartile range), and P values were evaluated by two-tailed Mann-Whitney U-test.
†Signiﬁcant differences.
‡Nearly signiﬁcant difference.
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e66 Cauci et al(CAG)20e24 carriers had a lower frequency (18.9%), whereas
the short extreme (CAG)9e19 (50.0%, OR ¼ 4.3, P ¼ .017)
and long extreme (CAG)25e37 (63.6%, OR ¼ 7.5, P ¼ .008)
carriers had higher frequencies.
Table 4 presents signiﬁcant ﬁndings for (GGN)n repeats. Loss
of scrotal sensitivity was less frequent in the long (GGN)>23 vs
medium (GGN)23 and medium to short (GGN)23 (69.2%,
P ¼ .031) subgroups. No subject with long (GGN)>23 repeats
reported scrotal discomfort vs 34.1% of subjects with medium
(GGN)23 (P ¼ .012) and 32.7% with medium to short
(GGN)23 repeats (P ¼ .014). Penile discomfort was less
frequent for long (GGN)>23 than for medium to short
(GGN)23 repeats (34.6%, P ¼ .05). Less pubic hair had an
OR equal to 8.8 compared with short (GGN)<23 (62.5%) and
medium (GGN)23 (15.9%), and a OR equal to 8.0 vs medium
to long (GGN)23 repeats (17.2%, P ¼ .012). All eight subjects
(100%) with short (GGN)<23 repeats reported the loss of
perineal fullness vs 57.1% of subjects with long (GGN)>23
repeats (P ¼ .05). Loss of muscle tone was reported by 87.5% of
short (GGN)<23 vs 45.5% of medium (GGN)23 carriers
(P ¼ .05). Moreover, skin dryness was more commonly reported
(87.5%) in the short (GGN)<23 than in the medium (GGN)23
(OR¼ 21), long (GGN)>23 (OR ¼ 12.6), and medium to long
(GGN)23 (OR ¼ 18.4) subgroups. Onset of symptoms soon
after ﬁnasteride discontinuation occurred more frequently in
subjects with long (GGN)>23 (28.6%) vs medium (GGN)23
(4.5%, OR ¼ 8.4) and medium to short (GGN)23 (5.7%,
OR ¼ 6.4) repeats.DISCUSSION
In this study, we examined for the ﬁrst time in detail whether
speciﬁc symptoms experienced by men with PFS were related to
the length of two trinucleotide repeats polymorphic sites located
in the large exon 1 of the X-linked AR gene. The AR belongs to
the steroid hormone receptor superfamily and mediates androgen
functions.16 However, only a few studies have investigated
(CAG)n repeat length in relation to male sexual functions.
Recently, Tirabassi et al30 evaluated sexual function recovery
after testosterone replacement therapy in subjects with hypo-
gonadism and found that the AR CAG triplet number was
negatively associated with changes in improved erectile function,
sexual desire, intercourse satisfaction, and total score on the
15-item International Index of Erectile Function after therapy.
One study found a signiﬁcant association of longer (CAG)n with
higher total AMS scores in outpatients with sexual and aging
male symptoms and patients with psychosomatic or psychiatric
disorders but not in healthy control men older than 50 years.31
CAG and GGN polymorphisms were supposed to have a role
in AGA, but a meta-analysis exploring the association of (CAG)n
and (GGN)n with AGA reported no signiﬁcant ﬁndings.32
In our study, (CAG)n repeats spanned from 9 to 37; therefore,
none of the subjects had at least 40 repeats, a high value typicallySex Med 2017;5:e61ee71
Table 4. Comparison of subgroups of patients with post-ﬁnasteride syndrome according to AR gene (GGN)n, short, medium, and long repeats*
(GGN)<23
repeats,
short
(n ¼ 8)
(GGN)23
repeats,
medium
(n ¼ 44)
(GGN)>23
repeats,
long
(n ¼ 14)
GGN short vs
medium, OR
(95% CI), P value
GGN long vs medium,
OR (95% CI), P value
GGN short vs long,
OR (95% CI),
P value
GGN short vs
medium þ long,
OR (95% CI),
P value
GGN long vs medium
þ short, OR (95% CI),
P value
Loss of scrotal
sensitivity
6 (75.0) 30 (68.2) 5 (35.7) 1.40 (0.25e7.83),
1.00
0.26 (0.07e0.92),
.031‡
5.40 (0.78e37.5),
.18
1.97 (0.37e10.6),
.70
0.25 (0.07e0.85),
.031‡
Scrotal discomfort 2 (25.0) 15 (34.1) 0 (—) 0.64 (0.12e3.59),
1.00
0.012†,‡ 0.12† 0.96 (0.17e5.26),
1.00
0.014†,‡
Penile discomfort 3 (37.5) 15 (34.1) 1 (7.1) 1.16 (0.24e5.53),
1.00
0.15 (0.02e1.25),
.08§
7.80 (0.65e93.8),
.12
1.57 (0.34e7.37),
.68
0.14 (0.02e1.20),
.05‡
Less pubic hair 5 (62.5) 7 (15.9) 3 (21.4) 8.81 (1.70e45.6),
.011‡
1.44 (0.32e6.53),
.69
6.11 (0.90e41.6),
.08§
8.00 (1.64e39.0),
.012‡
0.91 (0.22e3.80),
1.00
Loss of perceived
perineal fullness
8 (100) 31 (70.5) 8 (57.1) 0.18† 0.56 (0.16e1.93),
.51
0.05†,‡,§ 0.09†,§ 0.44 (0.13e1.52),
.20
Loss of muscle
tone
7 (87.5) 20 (45.5) 7 (50.0) 8.40 (0.95e74.1),
.05‡
1.20 (0.36e4.00),
.77
7.00 (0.67e72.9),
.17
8.04 (0.93e69.5),
.055§
0.93 (0.28e3.01),
.90
Increased skin
dryness
7 (87.5) 11 (25.0) 5 (35.7) 21.0 (2.32e190),
.001‡
1.67 (0.46e6.05),
.50
12.6 (1.19e134),
.031‡
18.4 (2.09e161),
.002‡
1.05 (0.31e3.60),
1.00
Onset of
symptoms
after ﬁnasteride
use
1 (12.5) 2 (4.5) 4 (28.6) 3.50 (0.27e44.7),
.36
8.40 (1.34e52.5),
.026‡
0.42 (0.04e4.66),
.62
1.44 (0.15e14.1),
.57
6.40 (1.24e33.1),
.034‡
OR ¼ odds ratio.
*Dichotomous variables were reported as number (percentage) and OR (95% CI) and P values. P values were evaluated by two-tailed Pearson c2 or Fisher exact test, as appropriate.
†OR (CI) could not be determined because one group contained no subjects (0%) or all subjects (100%) for the speciﬁc variable.
‡Signiﬁcant values.
§Nearly signiﬁcant.
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e68 Cauci et alfound in Kennedy disease.20 In our patients with PFS, short
(CAG)n repeats showed a greater decrease in sexual desire and
libido (AMS item 17) than medium repeats, whereas long (CAG)
n repeats were associated with worse orgasm satisfaction (ASEX
item 5) than short repeats.
Furthermore, subjects with short (CAG)n repeats had scrotal
discomfort and increased sperm density less frequently than those
with medium or medium to long repeats. Curiously, involuntary
muscle spasms were more frequent in the long (CAG)n than in
the medium (OR ¼ 6.3) and medium to short (CAG)<25
(OR ¼ 5.5) subgroups.
In our study, body mass index did not differ according to
(CAG)n subgroup. However, there were more subjects with PFS
reporting increased weight after ﬁnasteride discontinuation in the
long (CAG)n than in the medium (OR ¼ 4.9) group. It is worth
noting that Corona et al27 associated low testosterone with
increased fat mass. Moreover, Tirabassi et al18,33 observed that of
men with hypogonadotropic hypogonadism, those with shorter
(CAG)n repeat length had a greater metabolic improvement
(including decreased body weight) in response to testosterone
replacement therapy. Therefore, it seems plausible that subjects
with PFS have decreased androgen levels and that those subjects
with long (CAG)n repeats were more susceptible to increased
body weight.
However, our subjects with PFS and short (CAG)9e19 re-
peats used ﬁnasteride for a shorter period than those with me-
dium to long (CAG)20 repeats. Moreover, almost all (CAG)
9e19 carriers (15 of 18, 83.3%) reported a severe decrease in
sexual desire or libido as indicated by a score of 5 on AMS item
17. Further studies are necessary to assess whether ﬁnasteride
induces more rapidly developing sexual toxic effects in short
(CAG)n carriers.
We observed an interesting U-proﬁle for increased skin dry-
ness; the medium (CAG)20e24 group had the lowest frequency,
whereas the short (OR ¼ 4.3) and long (OR ¼ 7.5) (CAG)n
groups had higher frequencies. Remarkably, skin dryness was
reported by users of ﬁnasteride against hirsutism34 and by users
of spironolactone, a drug used to treat hormonal acne by
inhibiting the AR.11 Androgens modulate the rate of cell turn-
over in the basal layer of the epidermis, the size and activity of
the sebaceous glands, the quality of sebaceous secretions, the rate
of hair growth, and stimulation of collagen production.11,35 AR
is present in ﬁbroblasts and keratinocytes of human skin. One
study found the highest androgen binding capacity in cytosol of
skin cells from the external genitalia and a lower capacity in
pubic skin.36 Further investigations are required to explore the
role of extreme length of (CAG)n repeats in individuals sus-
ceptibility to develop skin dryness after drug treatments. Our
ﬁndings of a curvilinear U-proﬁle concur with an in vitro study
showing that ARs containing short and long (CAG)n stretches,
respectively, displayed lower activity than the AR of median
(CAG)22 repeats.37 The rationale of an U-proﬁle is that AR is
optimally functional with a medium length of the polyglutamine(and/or poly-glycine) stretch. Longer or shorter amino acid
repeat stretches could modify optimal protein folding, leading to
a suboptimal activity of the receptor protein.6,17,23,38,39 By
extrapolation, this suggests that skin dryness after ﬁnasteride use
might be due to decreased AR activity. Interestingly, a meta-
analysis showed a non-linear association between AR CAG
repeat length and risk of male subfertility.38
In this study, subjects with PFS and long (GGN)>23 repeats
had a better condition regarding physical exhaustion or lacking
vitality, depressive mood, and the feeling of passing one’s peak
than those with medium (GGN)23 repeats. In addition, subjects
with PFS and long (GGN)>23 repeats less frequently had loss of
scrotal sensitivity and scrotal discomfort but more frequently
reported the onset of symptoms after ﬁnasteride discontinuation
than those with medium (GGN)23 repeats.
Short (GGN)<23 carriers showed a better proﬁle concerning
need for sleep and/or often feeling tired than medium (GGN)23
carriers but were much more likely to report less pubic hair
(OR ¼ 8.8), loss of muscle tone (OR ¼ 8.4), and increased skin
dryness (OR ¼ 21) than medium (GGN)23 carriers.
Overall, we found that the AR polymorphisms can affect
several symptoms of PFS. To our knowledge, such speciﬁc as-
sociations have not been explored previously, which is the reason
we cannot compare our results with those of other studies.
Our data showed that short and long (CAG)n and (GGN)n
repeats correlate in an unpredictable way with several conditions
related to male androgenicity; this could derive from the vast
array of genes that are up- or down-modulated by the AR.16,40,41
The (CAG)n and (GGN)n polymorphisms also are likely to be in
linkage disequilibrium with other polymorphic sites in the hu-
man genome, which in turn might determine the observed
effects.40 In line with observations made by other investigators,39
the present ﬁndings suggest that the general belief associating
long (CAG)n and (GGN)n repeats with a worse androgenic
condition18 should be taken with caution.39 In general, in-
vestigations on the inﬂuence of AR polymorphisms on speciﬁc
clinical features (ie, metabolic proﬁle, bone density, and body
composition) typically show very contradictory results.18,33 This
could be due to the concomitant effect of AR-related genetic
cofactors (apart from the two studied polymorphisms), which
have not been fully explored thus far and which can exert an
independent effect on clinical outcomes.40,41 It should be noted
at this point that the dimension of complexity of the regulation
and activities of nuclear receptors is being realized, and that
tissue-speciﬁc effects and epigenetic changes occurring in a single
individual can modulate the action of receptors.41,42 Therefore,
many more investigations are needed to disclose the biological
pathways relating molecular ﬁndings to phenotypes.41,43
In our study, we decided to go beyond a simple categori-
zation of (CAG)n and (GGN)n repeats as binary (ie, long or
short), and we looked at three categories—short, medium,
and long repeats—to obtain a better assessment of length
variations relating to patients’ conditions. Indeed, U-proﬁlesSex Med 2017;5:e61ee71
AR Polymorphisms and Post-Finasteride Syndrome e69have been observed in vitro,23,37 and a recent study reported
that some markers of male reproductive function in fertile
men show a curvilinear association with the CAG or GGN
repeat length.39 To our knowledge, ours is the ﬁrst clinical
study showing that a U-proﬁle for (CAG)n repeats is detect-
able for a speciﬁc human symptom (ie, increased skin dryness
after ﬁnasteride use). However, it should be noted that for
most of the examined symptoms, only one extreme of (CAG)
n and/or (GGN)n repeats behaved differently from the
medium length subgroup.
A limitation of this study is the limited number of subjects.
Larger studies are warranted to substantiate the present ﬁnding in
white and other ethnic groups. Larger investigations also could
assess haplotypes comprising all the possible combinations of
short, medium, and long (CAG)n plus short, medium, and long
(GGN)n repeats. A general limitation of this study work is that
some symptoms reported by patients with PFS could not be
objectively determined. Furthermore, the retrospective design of
our study did not allow a clinical assessment of these men before
ﬁnasteride use. Future studies are necessary to assess the AR
genetic proﬁle and testosterone levels in subjects who developed
PFS compared with subjects who did not develop adverse
symptoms after using ﬁnasteride against AGA.CONCLUSION
Causes and predisposing factors responsible for the develop-
ment of long-term adverse side effects in young men who used
low-dose ﬁnasteride against AGA remain an enigma. Several
symptoms were in common in more than 70% of patients with
PFS, but a plethora of other disturbances was reported by a
minority of patients, with some clearly related and some not to
androgenicity.
Our study showed that the length of two trinucleotide repeats
in the AR gene contribute to the frequency of some speciﬁc
symptoms reported by patients with PFS. The (CAG)n and
(GGN)n polymorphisms were involved in two speciﬁc symp-
toms (ie, scrotal discomfort and increased skin dryness); for other
symptoms, only one of the two polymorphisms was involved,
which is likely a reﬂection of the complex modulation of AR
activity.16,40
Our investigation using a precision medicine approach sug-
gested genetic implications in symptoms of patients with PFS.
Much more genetic and non-genetic research is necessary to
elucidate the pathophysiologic pathways leading to the onset and
persistence of adverse effects in former ﬁnasteride users.
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